BridgeBio Pharma Inc (NASDAQ:BBIO) shares, rose in value, with the stock price up by 0.77% to the previous day’s close as strong demand from buyers drove the stock to $27.56.
Actively observing the price movement in the last trading, the stock closed the session at $27.35. The value of beta (5-year monthly) was 1.05. Referring to stock’s 52-week performance, its high was $44.32, and the low was $11.75. On the whole, BBIO has fluctuated by -19.81% over the past month.
With the market capitalization of BridgeBio Pharma Inc currently standing at about $5.08 billion, investors are eagerly awaiting this quarter’s results, scheduled for May 02, 2024 – May 06, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.94, which is expected to increase to -$0.79 for fiscal year -$3.47 and then to about -$3.08 by fiscal year 2025. Data indicates that the EPS growth is expected to be 12.20% in 2025, while the next year’s EPS growth is forecast to be 11.20%.
According to the average forecast, sales growth in current quarter could jump up 536.90%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $139.53 million, representing an increase of 1,399.80% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were 1 upward and no downward review(s) in last seven days. We see that BBIO’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of BBIO currently trading nearly -15.64% and -20.90% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 32.85, while the 7-day volatility ratio is showing 4.06% which for the 30-day chart, stands at 5.83%. Furthermore, BridgeBio Pharma Inc (BBIO)’s beta value is 1.05, and its average true range (ATR) is 1.83.
A comparison of BridgeBio Pharma Inc (BBIO) with its peers suggests the former has fared considerably weaker in the market. BBIO showed an intraday change of 0.77% in last session, and over the past year, it grew by 93.40%%.
Data on historical trading for BridgeBio Pharma Inc (NASDAQ:BBIO) indicates that the trading volumes over the past 10 days have averaged 2.3 million and over the past 3 months, they’ve averaged 1.97 million. According to company’s latest data on outstanding shares, there are 175.08 million shares outstanding.
Nearly 25.96% of BridgeBio Pharma Inc’s shares belong to company insiders and institutional investors own 71.52% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 13.64 million shares as on Feb 29, 2024, resulting in a short ratio of 8.54. According to the data, the short interest in BridgeBio Pharma Inc (BBIO) stood at 7.76% of shares outstanding as of Feb 29, 2024; the number of short shares registered in Jan 31, 2024 reached 14.21 million. The stock has fallen by -31.73% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the BBIO stock heading into the next quarter.
